Christine Natasha Ryan
Direttore operativo presso GABATHER AB
Provenienza dei contatti di primo grado di Christine Natasha Ryan
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Christine Natasha Ryan tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| TAURUS ENERGY AB | Oil & Gas Production | Director/Board Member | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Stockholm | College/University | Corporate Officer/Principal Graduate Degree | |
| University of Lund | College/University | Doctorate Degree | |
| Vrije Universiteit Brussel | College/University | Doctorate Degree | |
| Danmarks Farmaceutiske Universitet | College/University | Doctorate Degree | |
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
| WNTRESEARCH AB | Pharmaceuticals: Other | Chief Executive Officer | |
Novartis Sverige AB
 Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| LIDDS AB | Pharmaceuticals: Major | Director/Board Member | |
Forskarpatent i Syd AB
 Forskarpatent i Syd AB Miscellaneous Commercial ServicesCommercial Services Forskarpatent i Syd AB specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. It holds a portfolio of projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets. It is involves in projects in pharmaceutical, technology, and food categories. The firm is categorized under patent agency operations. The company was founded on January 18, 1996 and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Balx 4 AB | Director/Board Member | ||
| Cardio Vax LLC | Director/Board Member | ||
| Jakten 7 AB | Director/Board Member | ||
PheroNet AB
 PheroNet AB Chemicals: AgriculturalProcess Industries PheroNet AB provides lures for insect monitoring. It offers insect pheromones for pest management, pheromone traps to detect harmful insect species in a crop, and synthetic pheromones for mating disruptions. Its products include adoxophyes orana, anarsia lineatella, bonagota cranaodes, cydia pomonella, cydia splendana, eupoecilia ambiguella, grapholita funebrana, grapholita lobarzewskii grapholita molesta, lobesia botrana, pammene rhediella, pandemis heparana, sparganothis pilleriana and spilonota ocellana. The company is headquartered in Alnarp, Sweden. | Chemicals: Agricultural | Chief Executive Officer | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
| Stockholms läns Landsting | General Government | Corporate Officer/Principal | |
| Accequa AB | Chairman | ||
| COMBIGENE AB | Pharmaceuticals: Major | Chairman | |
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | Pharmaceuticals: Major | Founder | |
| CYXONE AB | Pharmaceuticals: Major | Founder | |
| Swedish Confederation of Professional Associations | Corporate Officer/Principal | ||
Sinfonia Biotherapeutics AB
 Sinfonia Biotherapeutics AB BiotechnologyHealth Technology Sinfonia Biotherapeutics AB is a clinical stage company based in Huddinge, Sweden. The Swedish company develops biologics for the treatment of neuropathic pain. | Biotechnology | Director of Finance/CFO | |
| ECTIN RESEARCH AB | Biotechnology | Director of Finance/CFO | |
| Lead Discovery Malaysia Sdn. Bhd. | Chief Executive Officer | ||
| Galecto Biotech AB | Founder | ||
| Accequa GmbH | Director/Board Member | ||
| Noviga Research AB | Founder | ||
| Gabather Finans AB | Director/Board Member | ||
Melius Pharma AB
 Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Pharmaceuticals: Major | Director of Finance/CFO | |
| SENSIDOSE AB | Electronic Equipment/Instruments | Director of Finance/CFO | |
| BIOEXTRAX AB | Biotechnology | Director of Finance/CFO |
Statistiche
Distribuzione geografica
| Svezia | 29 |
| Danimarca | 4 |
| Belgio | 2 |
| Stati Uniti | 2 |
| Malesia | 2 |
Settori
| Health Technology | 14 |
| Consumer Services | 5 |
| Transportation | 3 |
| Commercial Services | 3 |
| Energy Minerals | 2 |
Posizioni
| Director/Board Member | 15 |
| Founder | 9 |
| Corporate Officer/Principal | 8 |
| Director of Finance/CFO | 7 |
| Chief Executive Officer | 6 |
Contatti più connessi
- Borsa valori
- Insiders
- Christine Natasha Ryan
- Connessioni Società
